The purpose of this study is to evaluate the effects of nicotinic alpha-7 MEM 3454 on P50 sensory gating in patients with Schizophrenia. The hypothesis is that MEM 3454 will normalize the P50 ratio. Data produced in this study will provide useful information regarding the value of P50 as an efficacy biomarker, and provide evidence for the optimal dosing of MEM 3454 for additional P50 studies.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
12
University of Colorado Health Sciences Center
Denver, Colorado, United States
Determine the utility of P50 sensory gating as an efficacy biomarker for nicotinic alpha-7 agonist such as MEM 3454.
Time frame: Pre-dosing and Day 1
• Investigate the safety and tolerability of MEM 3454 compared with placebo
Time frame: all time points
• Determine whether MMN correlates with P50.
Time frame: Pre-dose and day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
50 mg dose
Placebo dose